Jingu Financial News | Northeast Securities issued a research report stating that hutchmed (china) (00013) announced positive summary results for the SAVANNAHII study. The combination therapy of Tarvolanib (osimertinib) and Volvaritinib (savolitinib) in non-small cell lung cancer patients with disease progression after previous Tarvolanib treatment, with high levels of MET overexpression and/or amplification (defined as IHC90+ and/or FISH10+), showed a high, clinically significant, and durable improvement in ORR. The above data will be presented at an upcoming academic conference and shared with global regulatory institutions.
The bank stated that the SAVANNAH study is an ongoing randomized, global Phase II clinical trial sponsored by astrazeneca, aiming to evaluate the efficacy of the combination therapy of Volvaritinib and Tarvolanib in EGFR mutation, MET amplification, or overexpression local advanced or metastatic non-small cell lung cancer patients with disease progression after previous Tarvolanib treatment. To date, the study has enrolled over 360 patients at more than 80 research centers globally, including in North America, Europe, South America, and Asia. The primary endpoint is ORR. The preliminary positive ORR results of the SAVANNAH study were announced at the 2022 WCLC conference, with an ORR of 49% in all patients with high MET levels. The clinical results announced this time also show a high improvement in ORR, demonstrating the competitive effectiveness of savolitinib combination therapy as second-line treatment after osimertinib use. Partner astrazeneca plans to submit a marketing application to the FDA by the end of the year, having already obtained fast track designation. Savolitinib is expected to become the company's second product to enter the international market after fruquintinib, continuing to expand overseas markets.
The bank mentioned that the company has a rich pipeline reserve, a wide product market space, and is expected to continuously achieve overseas sales growth. The bank expects the company to achieve revenues of 0.729/0.866/1 billion US dollars in 2024-2026, with EPS of -0.06/0.05/0.18 US dollars, maintaining a 'buy' rating on the company.
